Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Defends AER Nondisclosure In Supreme Court Brief

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives argues shareholder respondents "fundamentally misconceive" the materiality standard, and defends its nondisclosure of adverse events that are not statistically significant in a reply brief filed in ongoing Supreme Court litigation.

You may also be interested in...



Matrixx Bought By Private Equity Firm H.I.G., Settles Personal Injury Lawsuits

Matrixx Initiatives announced Dec. 14 private equity firm H.I.G. Capital will acquire the Scottsdale, Ariz.-based maker of Zicam cough/cold products for approximately $75.2 million.

Government Weighs In For Shareholders In Matrixx Supreme Court Case

The federal government says materiality should be the standard for deciding when firms must disclose information about problems to shareholders, arguing that Matrixx Initiatives presents a "false choice" between disclosing all information or only that considered statistically significant.

Matrixx Misled Shareholders About Zicam Problems, Investors Allege

Shareholders in litigation against Matrixx Initiatives pending in the U.S. Supreme Court say a reasonable person's decision on whether information about a firm is important – not a statistical significance measure – should be the standard for determining when a company must reveal problems with a product.

Related Content

Topics

UsernamePublicRestriction

Register

PS104756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel